For the Quarter Ending June 2025
North America
• The Dolutegravir Sodium (IP) Price Index in North America registered a slight downward movement during June 2025, reflecting persistent weakness in the Spot Price due to subdued buying momentum.
• Why did the price change in June 2025? The price declined as ample inventory levels, improved import logistics, and falling input costs pressured regional suppliers to lower quotes.
• The Spot Price softened throughout the month, with distributors adjusting offers downward to remain competitive against increased low-cost imports.
• The Dolutegravir Sodium Price Forecast for Q3 2025 indicates a potential rebound, backed by anticipated recovery in prescription volumes and a gradual tightening of available stock among wholesalers.
• The Dolutegravir Sodium Production Cost Trend remained favorable due to declining global API prices and stable operational expenses across North American formulation facilities.
• The Dolutegravir Sodium Demand Outlook was relatively muted, as procurement remained limited to short-cycle orders amid cautious inventory management by healthcare institutions and pharmacy chains.
• Why did the price change in July 2025 – increase or decrease? The price increased in July 2025 due to renewed prescription demand, early restocking by hospitals, and a mild rise in API procurement costs.
Europe
• The Dolutegravir Sodium (IP) Price Index in Europe trended downward in June 2025 amid weakened Spot Price levels and oversupplied conditions across key markets, including Germany.
• Why did the price change in June 2025? The decline was driven by subdued end-user demand, excess inventory at distributor levels, and competitive pricing from parallel import channels.
• The Dolutegravir Sodium Spot Price fell gradually through the month, as suppliers in the region offered discounts to stimulate movement in a slow, overstocked market.
• The Dolutegravir Sodium Price Forecast for Q3 2025 suggests limited upside potential unless procurement volumes increase or excess inventories are cleared across European pharmaceutical supply chains.
• The Production Cost Trend remained steady, though manufacturers reported lower margins due to pricing pressure and limited cost pass-through in a competitive environment.
• The Demand Outlook remained soft, as hospital tenders and generic procurement programs in Germany and surrounding EU nations focused on existing stock rotation rather than fresh orders.
• Why did the price change in July 2025 – increase or decrease? The price increased in July 2025 due to reduced inventory levels, early Q3 procurement activity, and slightly firmer API costs passed through the supply chain.
APAC
• The Dolutegravir Sodium (IP) Price Index in India recorded a slight decline in June 2025, settling at USD 174,134/MT Ex-Hyderabad due to softened Spot Price levels and reduced procurement appetite.
• Why did the price change in June 2025? The price declined as improved supply chain efficiency, high inventory levels, and softened input inflation collectively pressured prices downward.
• The Dolutegravir Sodium Spot Price weakened amid discounting by suppliers seeking to clear excess stock, while buyers focused only on immediate requirements.
• The Dolutegravir Sodium Price Forecast for Q3 2025 indicated a likely upward movement, driven by expectations of higher export orders and restocking by downstream pharmaceutical units.
• The Production Cost Trend remained stable, supported by optimal manufacturing operations, falling raw material prices, and increased domestic API availability.
• The Dolutegravir Sodium Demand Outlook showed a modest decline, as buyers adopted a conservative approach due to shortened lead times and ample on-hand inventories.
• Why did the price change in July 2025? The price increased in July 2025 due to strengthening export demand, rising input costs, reduced discounting, and renewed restocking activity.
For the Quarter Ending March 2025
North America
The U.S. Dolutegravir market experienced price fluctuations throughout Q1 2025, driven by shifting procurement trends, trade policy developments, and changing downstream demand. In January, prices moved upward as pharmaceutical companies front-loaded purchases in anticipation of supply disruptions tied to the Lunar New Year and early-year logistical bottlenecks. Higher freight rates and steady demand for antiretroviral therapies added to cost-side pressures, while limited spot availability prompted more aggressive procurement from key distributors.
February marked a shift in sentiment, with pricing easing as supply conditions improved and shipping costs from Asia began to moderate. Although a 10% tariff on Chinese pharmaceutical imports came into effect, several exporters adjusted their pricing to remain competitive, helping temper the impact on U.S. import costs. At the same time, softer offtake from hospitals and public health programs, along with constrained federal healthcare spending, led to more conservative buying behavior and moderated market momentum.
By March, prices continued to fluctuate as oversupply conditions became more evident. Declining export offers from China, coupled with sustained weakness in the U.S. Manufacturing PMI and a pullback in public sector procurement, contributed to a more subdued market tone. Retaliatory tariff announcements added further uncertainty, prompting some buyers to delay decisions. Overall, the U.S. Dolutegravir market in Q1 2025 reflected a trajectory of early firmness followed by cautious retracement, influenced by evolving cost inputs, shifting demand patterns, and complex global trade developments.
Asia Pacific
In Q1 2025, Dolutegravir prices in the Indian market followed a distinct three-phase trend—beginning with a strong upward surge in January, followed by consecutive declines in February and March. January saw a sharp increase in prices, supported by robust demand from the pharmaceutical, personal care, and food and beverage sectors. Consumer interest in health and wellness products surged, driving the use of Dolutegravir as a functional ingredient. Despite global supply chain improvements and steady import flows, tightening international availability and elevated production costs intensified pricing pressure.
In contrast, February experienced a notable price correction. The January spike led buyers to pause procurement and reassess their inventory positions. Simultaneously, oversupply in the domestic market, coupled with price competition from lower-cost Chinese exports, placed further pressure on Indian sellers. A dip in India’s inflation rate to 4.1% and weaker industrial activity dampened market sentiment. The slowdown in pharmaceutical production and reduced export demand compounded the softening trend, resulting in a steep price decline.
The downward trajectory persisted in March, with prices falling by 3.23% due to improved supply-side dynamics. Government support via the PLI scheme boosted domestic production, while enhanced logistics and lower raw material costs increased operational efficiency. However, soft demand from the pharmaceutical sector led to inventory buildup, prompting aggressive price reductions. Competitive pricing strategies and cautious buyer behavior further reinforced the bearish sentiment. Overall, Q1 closed with a clear shift from a demand-driven surge to supply-led price moderation in the Indian Dolutegravir market.
Europe
The German Dolutegravir market exhibited fluctuating pricing patterns across Q1 2025, reflecting evolving procurement behavior, global supply dynamics, and shifting downstream demand. In January, prices showed modest upward movement as pharmaceutical manufacturers accelerated purchases ahead of the Lunar New Year in Asia. This front-loaded procurement strategy, aimed at mitigating potential disruptions in supply chains, supported consistent offtake. Simultaneously, elevated freight rates and tight container availability contributed to increased landed costs, influencing early-quarter pricing sentiment despite stable domestic inventories.
February brought a shift in momentum, with pricing reflecting more tempered market activity. The impact of January's inventory buildup became more pronounced, leading to a slowdown in fresh procurement. Buyers adopted a more selective purchasing strategy, influenced by softening demand signals and slightly improved shipping conditions. At the same time, a depreciating euro added to import cost volatility, encouraging caution in pricing negotiations across key pharmaceutical supply chains.
By March, prices fluctuated again as bearish market fundamentals emerged. A combination of stable supply inflows, easing export offers from major producing countries, and reduced urgency from downstream sectors contributed to a softer tone. Additionally, macroeconomic uncertainty and subdued production activity weighed on buyer sentiment. Despite marginal improvements in logistics efficiency, oversupply and restrained offtake kept pricing trends on a downward path. Overall, the German Dolutegravir market in Q1 2025 transitioned from early-quarter firmness to late-quarter caution, shaped by evolving demand conditions and shifting cost pressures.
For the Quarter Ending December 2024
North America
The U.S. Dolutegravir market experienced notable price declines in Q4 2024, driven by market saturation, reduced demand, and intensified competition among suppliers. Oversupply, coupled with stable raw material availability and lower production costs, allowed manufacturers to lower prices. Disruptions from hurricanes and port strikes further pressured the market, while cautious procurement from end-users added to the downward trend.
By November, reduced inventories, lower export prices, and holiday discounts from suppliers deepened the price decline. However, improvements in supply chain operations, such as enhanced inventory management and increased port activity, helped stabilize the market. Although the Manufacturing PMI showed a slight recovery, it remained in contraction, reflecting ongoing weaknesses in manufacturing activity.
These factors combined to create a dynamic market environment, with challenges in demand and supply chain disruptions influencing pricing trends. Moving forward, the market is likely to remain under pressure, requiring ongoing adjustments to maintain stability and navigate a competitive landscape.
Asia
The Indian Dolutegravir market demonstrated significant volatility in Q4 2024, driven by a pronounced demand-supply imbalance and evolving market dynamics. October saw bullish momentum fueled by constrained production, labor shortages, and robust downstream demand ahead of winter. Prices surged as industrial demand outpaced speculative activity, with spot market premiums reflecting structural strength rather than short-term fluctuations. Manufacturing PMI rose to 57.5 in October, signaling robust growth despite rising cost pressures.
In November, prices climbed further amid seasonal demand, escalating production costs, and a depreciating Indian Rupee. Procurement intensified, supporting a seller-dominated market with elevated premiums. PMI dipped to 56.5, reflecting moderated growth amid inflationary headwinds.
December marked a strategic price correction as deliberate destocking and stable downstream demand eased pressure. PMI slid to 56.4, the lowest in 12 months, signaling softened growth as businesses adapted to competition and cost pressures. While the market faces challenges, resilience in managing supply shifts and long-term strategies position it for sustained growth in 2025. By the end of Q4, the latest price for Dolutegravir Sodium (IP) Ex-Hyderabad was recorded at USD 190749.25 per metric ton with an average quarterly decline of 1.09%, reflecting the prevailing negative sentiment in the pricing environment and reinforcing concerns about future market stability.
Europe
In Q4 2024, Europe’s Dolutegravir market saw notable price fluctuations, heavily influenced by its reliance on imports from India. The depreciation of the Indian Rupee allowed European importers to secure competitively priced shipments, fostering pricing advantages across the region. However, this dependency also heightened market sensitivity to currency dynamics, shaping procurement strategies.
Meanwhile, Germany’s Dolutegravir market experienced volatility, shifting from a bearish trend to upward price pressures by the quarter's close. Weak demand, reduced production costs, and oversupply initially forced producers to adopt discounting strategies to manage inventories. Financial constraints among importers and conservative purchasing behaviors further contributed to subdued activity. Competitive freight rates and a stronger euro added to downward price pressures.
Compounding these challenges, Europe’s manufacturing sector faced stagnation, with the PMI fixed at 43, reflecting a contracting industrial landscape. Despite these hurdles, the Dolutegravir and Dolutegravir markets showcase the region’s ability to adapt, offering strategic opportunities for growth amid fluctuating market conditions.
For the Quarter Ending September 2024
North America
In Q3 2024, the U.S. market for Dolutegravir exhibited notable downward trends, primarily influenced by its significant reliance on Indian-manufactured active pharmaceutical ingredients (APIs). This market experienced benefits from competitive pricing offered by Indian manufacturers, which enabled U.S. companies to maintain lower costs. However, these advantages were somewhat diminished by rising logistics costs and increased import duties, which added financial strain to the supply chain.
Throughout the quarter, U.S. pharmaceutical firms strategically managed their inventory levels, choosing to postpone significant purchases in anticipation of further price declines. This tactical approach led to a -17% price change compared to the previous quarter, underscoring the market's sensitivity to pricing dynamics. The price differential between the first and second halves of Q3 was recorded at -3.5%, further illustrating the consistent downward pressure exerted on Dolutegravir prices.
By the end of Q3, the latest quoted price for Dolutegravir Sodium (IP) DDP-New Jersey reached USD 17,850,000 per metric ton. This figure reflects the incorporation of additional import-related costs while also embodying the prevailing bearish market sentiment that continues to emanate from the Asian market.
Asia
In Q3 2024, the APAC region faced significant challenges regarding Dolutegravir pricing, marked by a considerable decline in market rates. This downturn can be attributed to several converging factors. Notably, decreased industrial output across various sectors, including pharmaceutical excipients, created an oversupply that exerted downward pressure on prices. Concurrently, currency fluctuations, particularly the depreciation of the Indian Rupee, affected pricing dynamics, rendering domestically produced excipients more competitive on the global stage.
Demand also softened during the quarter, with end-users displaying reluctance to procure, which further contributed to a pessimistic market outlook. In India, substantial price changes were observed, with stable production levels offset by declining prices. The quarter recorded a remarkable -20% price change compared to the previous quarter, highlighting sustained downward momentum. Additionally, a -4% price difference between the first and second halves of the quarter underscored the consistent decline.
By the end of Q3, the latest price for Dolutegravir Sodium (IP) Ex-Hyderabad was recorded at USD 16,450,000 per metric ton, reflecting the prevailing negative sentiment in the pricing environment and reinforcing concerns about future market stability.
Europe
In Q3 2024, the European market for Dolutegravir experienced significant price fluctuations, largely due to its reliance on imports from Indian suppliers. This dependency has made the region sensitive to currency shifts, particularly as Indian exporters benefited from a depreciation of the Indian Rupee. Consequently, European importers capitalized on this currency advantage, resulting in more competitive pricing for Dolutegravir imports.
Throughout the quarter, European pharmaceutical manufacturers exhibited cautious purchasing behavior, opting for a wait-and-watch strategy in light of declining price trends in the Indian market. This prudent approach contributed to an overall price decrease of 15% compared to the previous quarter. A more detailed intra-quarter analysis revealed a 3% decline between the first and second halves, underscoring a steady downward trajectory.
By the end of Q3, the recorded price for Dolutegravir Sodium (IP) DDP-Rotterdam stood at USD 17,250,000 per metric ton. This figure reflects the complex interplay of Asian market dynamics and additional costs associated with imports, emphasizing the challenges faced by European buyers in navigating this evolving landscape.
FAQ’s
Why did Dolutegravir Sodium (IP) prices decline in APAC during June 2025?
Prices in the APAC region declined due to high inventory levels, lower production costs, and improved supply chain efficiency. Discounting by suppliers in India to clear excess stock contributed to a softer Spot Price, dragging down the regional Price Index.
What led to the price increase of Dolutegravir Sodium (IP) in APAC during July 2025?
The price rose in July 2025 driven by renewed export orders, rising API input costs, and pre-Q3 restocking by pharmaceutical manufacturers in India, tightening supply and lifting the Spot Price.
Why did the North American market see a drop in Dolutegravir Sodium (IP) prices during June 2025?
In North America, Dolutegravir Sodium (IP) prices fell due to subdued downstream demand, improved import availability, and lower global API prices. Spot Price corrections were common as suppliers aimed to remain competitive amid soft regional procurement.
What factors caused Dolutegravir Sodium (IP) prices to increase in North America in July 2025?
The price increase was fueled by rising prescription volumes, early restocking activity by hospital networks, and a mild uptick in API costs that pushed the Spot Price upward despite stable production costs.
Why did Dolutegravir Sodium (IP) prices remain under pressure in Europe during June 2025, especially in Germany?
In Europe, and particularly in Germany, the June decline was attributed to excess stock, weak tender-based demand, and price competition from parallel import channels. Despite stable production costs, the Price Index declined due to limited offtake and discounted Spot Prices.
